Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Newark, Delaware

4 studies are recruiting for non-small cell lung cancer (nsclc) in Newark, Delaware right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark, Delaware
    Locations
    418 in total
    Run by
    Amgen

    See if you can join NCT05920356 on ClinicalTrials.gov

  2. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Medical Oncology Hematology Consultants, PA, Newark, Delaware
    Locations
    259 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07361497 on ClinicalTrials.gov

  3. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Newark, Delaware
    Locations
    206 in total
    Run by
    AstraZeneca

    See if you can join NCT07291037 on ClinicalTrials.gov

  4. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Exelixis Clinical Site #49, Newark, Delaware
    Locations
    122 in total
    Run by
    Exelixis

    See if you can join NCT05176483 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.